Shots: The approval follows the P-II study which involves assessing of Trodelvy in 108 adults with TNBC who had previously received a median of three prior systemic therapies in the […]readmore
Tags : Metastatic Triple-Negative Breast Cancer
Shots: The P-III KEYNOTE-355 (part 1 & 2) study involves assessing of Keytruda (200mg, IV, on day 1 of each 21-day cycle) + CT vs PBO + CT in 30 […]readmore
Shots: The US FDA has accepted resubmission of BLA, seeking accelerated approval of sacituzumab govitecan to treat patients with mTNBC, prior treated with at least two therapies for metastatic disease, […]readmore